about
Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybridsPyranopyrazolotacrines as nonneurotoxic, Aβ-anti-aggregating and neuroprotective agents for Alzheimer's disease.Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer's disease therapy.Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity.Chemical and pharmacological studies on enantiomerically pure p-methoxytacripyrines, promising multi-target-directed ligands for the treatment of Alzheimer's disease.Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy.Dendrimer-functionalized electrospun nanofibres as dual-action water treatment membranes.Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases.Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapy.Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease.Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.Harmaline and hispidin from Peganum harmala and Inonotus hispidus with binding affinity to Candida rugosa lipase: In silico and in vitro studies.Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's DiseaseTacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease5-Methyl--(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5-indolo[2,3-]quinolin-11-amine: a highly potent human cholinesterase inhibitorSynthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analoguesMultipotente Liganden mit kombinierter Cholinesterase- und Monoaminooxidase-Inhibition sowie Histamin-H3 R-Antagonismus bei neurodegenerativen ErkrankungenSynthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapyDonepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapyQuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease TherapyContilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism ProfileTackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenaseDiscovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment
P50
Q31087536-B7954C92-7BBA-493E-BFF0-551948BF836FQ34394212-D7C3E15F-D17F-4C37-9747-87231E64947BQ35659603-FD1AE901-DC26-4559-B933-D3A79E96A960Q36371931-0DA95F19-4712-4103-88DC-058CD021E06EQ39199947-A6C27061-7676-4E07-8D9F-3E4235332EF0Q39459684-BB65342C-1D61-475F-8202-EDEF6ED9ACDCQ39688701-5AD14ED0-B31B-4791-89F0-3FD26F1B0F84Q46141581-9A70F43A-B65B-4856-8545-F83956B27B5BQ48018674-E9A85677-02AA-4749-9F59-4475DD357188Q48130975-4E669126-27FB-450A-9A82-5835D7DD1FAAQ48405787-0535ED1F-ABCE-4E1C-8314-897FA24186CFQ48440635-66CCACF5-9292-4B85-B554-21EBE3D5C2CCQ48782802-510D63CE-8D4E-47F7-9399-9FBA0061A351Q51016511-855E9F44-0E0B-4216-92B0-5F83BD985D30Q53349275-22749417-F014-4C0A-A990-D8783EC59BE7Q53425810-5804E233-DC8A-4D8E-A390-667C93D28371Q53436226-32EF7F3F-B976-4E50-8064-594AEFF8B2F2Q53437346-18A894EF-657C-4245-8F72-C88337A82155Q56361601-A760DDA2-2FDE-453C-8C52-630F75EB8432Q56365493-698B44F8-BACB-447D-BF54-C1844870962FQ56960330-FE4751AC-B7B6-4555-A213-9C743CBC6AD8Q58010802-E6852622-0B9F-4D58-8D27-C40D2F9C9D91Q59505514-EEFACF0F-3D9A-4302-B091-89DDA3CAF7D8Q59807620-9864C935-5D8C-45C8-9FA1-4453A4475A7BQ61800275-1E1E5677-A663-46F2-9F0F-EF1BFCBD1817Q64249983-FF28A9B9-DD2A-4223-9268-4A44072165B9Q89401950-DC772E35-DCA3-46AC-BCBF-64B742A525D6Q91643088-3246124A-114D-406A-BEF2-77A72C12416AQ92660389-E2CDEDB1-C51C-4AD3-8DB1-1617E8443BD5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ignacio Moraleda
@ast
Ignacio Moraleda
@en
Ignacio Moraleda
@es
Ignacio Moraleda
@nl
Ignacio Moraleda
@sl
type
label
Ignacio Moraleda
@ast
Ignacio Moraleda
@en
Ignacio Moraleda
@es
Ignacio Moraleda
@nl
Ignacio Moraleda
@sl
prefLabel
Ignacio Moraleda
@ast
Ignacio Moraleda
@en
Ignacio Moraleda
@es
Ignacio Moraleda
@nl
Ignacio Moraleda
@sl
P106
P21
P31
P496
0000-0001-8032-5689